KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Krystal Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$320.25+3.67 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- 40.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
30M of 30M shares
Institutional holders
422
94 new, 36 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 142 sales
Net sold $105.27M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 4,292,881 | 14.94% | 13G (passive) amendment | Nov 12, 2024 |
| BlackRock, Inc. | 3,947,588 | 13.80% | 13G (passive) amendment | Jun 30, 2024 |
| Krish S. Krishnan | 3,388,283 | 11.50% | 13G (passive) amendment | Mar 31, 2026 |
| Avoro Capital Advisors LLC | 2,565,555 | 9.10% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Portfolio Management | 1,479,111 | 5.05% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of KRYS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 4,418,197 | 14.93% | $1.64B | +44,210 | 0.07% |
| BlackRock, Inc. | 4,181,432 | 14.13% | $1.55B | +240,976 | 0.02% |
| Avoro Capital Advisors LLC | 2,888,888 | 9.76% | $1.07B | – | 9.64% |
| Vanguard Portfolio Management LLC | 1,574,905 | 5.32% | $585.34M | +118,178 | 0.03% |
| State Street Corp | 1,351,158 | 4.56% | $502.20M | +36,724 | 0.01% |
| Vanguard Capital Management LLC | 1,240,567 | 4.19% | $461.08M | +75,243 | 0.01% |
| Soleus Capital Management, L.P. | 939,254 | 3.17% | $349.09M | −213,833 | 12.03% |
| Capital World Investors | 777,843 | 2.63% | $289.10M | −46,877 | 0.03% |
| Vestor Capital, LLC | 700,914 | 2.37% | $78.19K | +700,714 | 4.88% |
| Geode Capital Management, LLC | 698,993 | 2.36% | $259.84M | +55,018 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 687,400 | 2.32% | $255.49K | +202,326 | 0.03% |
| Hood River Capital Management LLC | 663,375 | 2.24% | $246.56M | +43,789 | 1.79% |
| Redmile Group, LLC | 632,005 | 2.14% | $234.90M | −41,500 | 15.77% |
| William Blair Investment Management, LLC | 570,153 | 1.93% | $211.91M | +162,975 | 0.64% |
| Frazier Life Sciences Management, L.P. | 481,307 | 1.63% | $178.89M | – | 3.90% |
| Dimensional Fund Advisors LP | 476,038 | 1.61% | $176.94M | +7,048 | 0.03% |
| First Trust Advisors LP | 324,900 | 1.10% | $120.76M | −25,621 | 0.07% |
| Invesco Ltd. | 324,755 | 1.10% | $120.70M | +73,382 | 0.01% |
| Goldman Sachs Group Inc | 298,841 | 1.01% | $111.07M | +83,892 | 0.01% |
| Northern Trust Corp | 283,784 | 0.96% | $105.47M | +31,321 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 422 | 30M | 100.0% | 94 / 176 | 109 / 36 | 3M | 1M |
| Q1 2026 | 368 | 28M | 95.9% | 76 / 138 | 105 / 36 | 4M | 2M |
| Q4 2025 | 334 | 28M | 96.2% | 82 / 112 | 104 / 27 | 2M | 2M |
| Q3 2025 | 284 | 28M | 95.1% | 46 / 107 | 86 / 32 | 2M | 2M |
| Q2 2025 | 275 | 28M | 93.4% | 42 / 101 | 97 / 63 | 3M | 3M |
| Q1 2025 | 299 | 28M | 93.5% | 64 / 89 | 112 / 27 | 2M | 2M |
| Q4 2024 | 264 | 28M | 93.8% | 37 / 94 | 98 / 52 | 1M | 2M |
| Q3 2024 | 283 | 28M | 96.0% | 55 / 106 | 89 / 15 | 6M | 2M |
| Q2 2024 | 245 | 29M | 98.3% | 52 / 99 | 72 / 40 | 5M | 2M |
| Q1 2024 | 234 | 26M | 89.0% | 66 / 63 | 82 / 25 | 4M | 3M |
| Q4 2023 | 194 | 26M | 86.4% | 29 / 73 | 65 / 20 | 4M | 3M |
| Q3 2023 | 188 | 24M | 82.7% | 21 / 89 | 52 / 14 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of KRYS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 1,802,622 | 6.09% | $557.06M | 10.58% | May 31, 2026 |
| iShares Core S&P Small-Cap ETF | 1,580,327 | 5.34% | $587.36M | 0.53% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 889,548 | 3.01% | $330.62M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company Fund | 788,525 | 2.66% | $243.68M | 0.25% | May 31, 2026 |
| SMALLCAP World Fund Inc | 752,244 | 2.54% | $279.59M | 0.30% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 670,870 | 2.27% | $249.34M | 0.30% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 642,490 | 2.17% | $238.79M | 0.13% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 370,503 | 1.25% | $137.70M | 0.29% | Jun 30, 2026 |
| Hood River Small-Cap Growth Fund | 329,780 | 1.11% | $122.57M | 1.84% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 318,741 | 1.08% | $118.47M | 1.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 301,179 | 1.02% | $111.94M | 0.11% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 293,036 | 0.99% | $108.91M | 3.87% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 285,631 | 0.97% | $97.43M | 0.29% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 241,279 | 0.82% | $89.68M | 0.58% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 240,760 | 0.81% | $89.48M | 0.53% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Krish S. Krishnan | President and CEO, Director, 10% owner | 1,567,863 | 5.30% | Sep 4, 2026 |
| Suma Krishnan | President, R&D, Director, 10% owner | 1,512,362 | 5.11% | Sep 4, 2026 |
| John Charles Thomas | EVP, General Counsel | 1,000 | 0.00% | Jun 26, 2026 |
| Laurent Louis Jean Goux | EVP, Head of International | 919 | 0.00% | Mar 6, 2026 |
| Kathryn Romano | Chief Accounting Officer | 22,366 | 0.08% | Mar 3, 2026 |
| Everett Rand Sutherland | Director | – | – | Sep 16, 2026 |
| Daniel Janney | Director | 76,409 | 0.26% | Sep 16, 2026 |
| Catherine Mazzacco | Director | – | – | Sep 16, 2026 |
| Dino A. Rossi | Director | 75,000 | 0.25% | Sep 16, 2026 |
| Julian S. Gangolli | Director | 20,000 | 0.07% | Sep 16, 2026 |
| Christopher Mason | Director | – | – | Sep 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,267 | $356.37 | $1.16M | 1,321,352 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −399 | $366.56 | $146.26K | 1,302,145 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −826 | $365.41 | $301.83K | 1,302,544 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,329 | $364.48 | $484.39K | 1,303,370 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −520 | $354.54 | $184.36K | 1,326,625 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,006 | $355.57 | $713.27K | 1,324,619 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −565 | $363.34 | $205.29K | 1,304,699 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,962 | $357.57 | $1.42M | 1,317,390 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,180 | $358.42 | $1.14M | 1,314,210 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,392 | $359.39 | $1.22M | 1,310,818 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,320 | $360.47 | $836.29K | 1,308,498 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,242 | $361.61 | $449.12K | 1,307,256 |
| Suma Krishnan President, R&D, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,992 | $362.65 | $722.40K | 1,305,264 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −573 | $363.34 | $208.19K | 1,350,153 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,010 | $362.65 | $728.93K | 1,350,726 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,214 | $361.61 | $438.99K | 1,352,736 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,266 | $360.46 | $816.80K | 1,353,950 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,357 | $359.39 | $1.21M | 1,356,216 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,143 | $358.42 | $1.13M | 1,359,573 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,981 | $357.57 | $1.42M | 1,362,716 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −3,297 | $356.37 | $1.17M | 1,366,697 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −2,029 | $355.57 | $721.45K | 1,369,994 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −520 | $354.54 | $184.36K | 1,372,023 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −405 | $366.56 | $148.46K | 1,347,543 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −847 | $365.42 | $309.51K | 1,347,948 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Sep 4, 2026 | Sale(10b5-1 plan) | −1,358 | $364.48 | $494.96K | 1,348,795 |
| Dino A. Rossi Director | Aug 14, 2026 | Gift | −3,691 | – | – | 75,000 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −341 | $325.60 | $111.03K | 74,659 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −2,287 | $326.60 | $746.93K | 72,372 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −5,226 | $327.39 | $1.71M | 67,146 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −1,687 | $328.52 | $554.21K | 65,459 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −7,428 | $329.60 | $2.45M | 58,031 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −4,896 | $330.36 | $1.62M | 53,135 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −3,095 | $331.43 | $1.03M | 50,040 |
| Dino A. Rossi Director | Aug 14, 2026 | Sale | −40 | $333.23 | $13.33K | 50,000 |
| John Charles Thomas EVP, General Counsel | Jun 25, 2026 | Option exercise | +1,000 | $179.25 | $179.25K | 1,000 |
| John Charles Thomas EVP, General Counsel | Jun 25, 2026 | Sale(10b5-1 plan) | −1,000 | $347.27 | $347.27K | 0 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −1,348 | $307.09 | $413.96K | 1,399,767 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,039 | $310.94 | $634.01K | 1,378,395 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,801 | $309.95 | $868.17K | 1,380,434 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −3,803 | $308.89 | $1.17M | 1,383,235 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −12,729 | $307.81 | $3.92M | 1,387,038 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −240 | $311.65 | $74.80K | 1,378,155 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −480 | $305.87 | $146.82K | 1,401,115 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −400 | $304.89 | $121.96K | 1,401,595 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −247 | $303.17 | $74.88K | 1,401,995 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −593 | $302.25 | $179.23K | 1,402,242 |
| Suma Krishnan President, R&D, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −320 | $300.75 | $96.24K | 1,402,835 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −11,461 | $307.68 | $3.53M | 1,461,523 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −589 | $306.33 | $180.43K | 1,472,984 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −544 | $304.81 | $165.82K | 1,473,573 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −4,830 | $308.47 | $1.49M | 1,456,693 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,784 | $309.49 | $861.62K | 1,453,909 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −2,652 | $310.43 | $823.26K | 1,451,257 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −964 | $311.36 | $300.15K | 1,450,293 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −40 | $312.23 | $12.49K | 1,450,253 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −176 | $303.17 | $53.36K | 1,474,117 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −640 | $302.24 | $193.43K | 1,474,293 |
| Krish S. Krishnan President and CEO, Director, 10% owner | Jun 4, 2026 | Sale(10b5-1 plan) | −320 | $300.75 | $96.24K | 1,474,933 |
| John Charles Thomas EVP, General Counsel | May 26, 2026 | Sale(10b5-1 plan) | −642 | $302.03 | $193.90K | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Krishnan Suma Director, Officer, 10% Stockholder | Sep 4, 2026 | 25,000 | $9.29M | Sep 4, 2026 | Founders Shares |
| Krishnan Krish Director, Officer, 10% Stockholder | Sep 4, 2026 | 25,000 | $9.29M | Sep 4, 2026 | Founders Shares |
| A. Rossi Dino Director | Aug 14, 2026 | 25,000 | $8.31M | Aug 14, 2026 | Acquired from public market |
| John Charles Thomas Officer | Jun 25, 2026 | 1,000 | $347.27K | Jun 25, 2026 | Stock Option Exercise |
| Krishnan Krish Director, Officer, 10% Stockholder | Jun 4, 2026 | 25,000 | $7.55M | Jun 4, 2026 | Founders Shares |
| Krishnan Suma Director, Officer, 10% Stockholder | Jun 4, 2026 | 25,000 | $7.55M | Jun 4, 2026 | Founders Shares |
| John Charles Thomas Officer | May 26, 2026 | 642 | $193.90K | May 26, 2026 | Restricted Stock Vesting |
| Krishnan Suma Director, Officer, 10% Stockholder | Mar 4, 2026 | 25,000 | $6.60M | Mar 4, 2026 | Founders Shares |
| Krishnan Krish Director, Officer, 10% Stockholder | Mar 4, 2026 | 25,000 | $6.60M | Mar 4, 2026 | Founders Shares |
| Kathryn Romano Officer | Mar 2, 2026 | 750 | $200.70K | Mar 2, 2026 | Restricted Stock Vesting |
| S. Janney Daniel Director | Feb 27, 2026 | 11,803 | $3.25M | Feb 27, 2026 | Private Placement |
| S. Janney Daniel Director | Feb 26, 2026 | 7,741 | $2.13M | Feb 26, 2026 | Private Placement |
| S. Janney Daniel Director | Feb 25, 2026 | 700 | $192.50K | Feb 25, 2026 | Private Placement |
| S. Janney Daniel Director | Feb 24, 2026 | 13,825 | $3.71M | Feb 24, 2026 | Private Placement |
| Daniel Janney Director | Feb 24, 2026 | 37,895 | $10.11M | Feb 24, 2026 | Option Granted 11/10/2016 |